Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.biopha.2021.112023 http://scihub22266oqcxt.onion/10.1016/j.biopha.2021.112023 34399199!8352658!34399199     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biomed+Pharmacother 2021 ; 142 (ä): 112023 Nephropedia Template TP {{tp|p=34399199|t=2021. Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations |pdf=|usr=}}{{34399199}} gab.com Text Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations JO: Biomed Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=34399199 #FOAvip The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the most recent coronaviruses, which has infected humans, and caused the disease COVID-19. The World Health Organization has declared COVID-19 as a pandemic in March 2020. The SARS-CoV-2 enters human hosts majorly via the respiratory tract, affecting the lungs first. In few critical cases, the infection progresses to failure of the respiratory system known as acute respiratory distress syndrome acute respiratory distress syndrome may be further associated with multi-organ failure and vasoplegic shock. Currently, the treatment of COVID-19 involves use of antiviral and anti-cytokine drugs. However, both the drugs have low efficacy because they cannot inhibit the production of free radicals and cytokines at the same time. Recently, some researchers have reported the use of methylene blue (MB) in COVID-19 management. MB has been used since a long time as a therapeutic agent, and has been approved by the US FDA for the treatment of other diseases. The additional advantage of MB is its low cost. MB is a safe drug when used in the dose of < 2 mg/kg. In this review, the applicability of MB in COVID-19 and its mechanistic aspects have been explored and compiled. The clinical studies have been explained in great detail. Thus, the potential of MB in the management of COVID-19 has been examined. Twit Text FOAVip Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations ????Biomed Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=34399199 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34399199 #FOAvip English Wikipedia <ref>{{Cite pmid|34399199}}</ref> Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations #MMPMID34399199 Dabholkar N; Gorantla S; Dubey SK; Alexander A; Taliyan R; Singhvi G Biomed Pharmacother 2021[Oct]; 142 (ä): 112023 PMID34399199show ga The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the most recent coronaviruses, which has infected humans, and caused the disease COVID-19. The World Health Organization has declared COVID-19 as a pandemic in March 2020. The SARS-CoV-2 enters human hosts majorly via the respiratory tract, affecting the lungs first. In few critical cases, the infection progresses to failure of the respiratory system known as acute respiratory distress syndrome acute respiratory distress syndrome may be further associated with multi-organ failure and vasoplegic shock. Currently, the treatment of COVID-19 involves use of antiviral and anti-cytokine drugs. However, both the drugs have low efficacy because they cannot inhibit the production of free radicals and cytokines at the same time. Recently, some researchers have reported the use of methylene blue (MB) in COVID-19 management. MB has been used since a long time as a therapeutic agent, and has been approved by the US FDA for the treatment of other diseases. The additional advantage of MB is its low cost. MB is a safe drug when used in the dose of < 2 mg/kg. In this review, the applicability of MB in COVID-19 and its mechanistic aspects have been explored and compiled. The clinical studies have been explained in great detail. Thus, the potential of MB in the management of COVID-19 has been examined. |*COVID-19 Drug Treatment[MESH] |*COVID-19/metabolism/virology[MESH] |*SARS-CoV-2/drug effects/physiology[MESH] |Antiviral Agents/pharmacology[MESH] |Drug Repositioning/*methods[MESH] |Enzyme Inhibitors/pharmacology[MESH] |Humans[MESH]Repurposing methylene blue in the management of COVID-19: Mechanistic (epmc).pdf DeepDyve Pubget Overpricing